General Partner Inc. Acquires 150 Shares of Amgen Inc. (NASDAQ:AMGN)

General Partner Inc. increased its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 119.0% in the fourth quarter, Holdings Channel.com reports. The fund owned 276 shares of the medical research company’s stock after buying an additional 150 shares during the quarter. General Partner Inc.’s holdings in Amgen were worth $72,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of AMGN. Lantz Financial LLC increased its position in shares of Amgen by 5.1% during the second quarter. Lantz Financial LLC now owns 1,779 shares of the medical research company’s stock worth $556,000 after acquiring an additional 87 shares during the period. nVerses Capital LLC bought a new stake in Amgen during the 2nd quarter valued at $31,000. Cozad Asset Management Inc. lifted its holdings in shares of Amgen by 11.8% in the 2nd quarter. Cozad Asset Management Inc. now owns 1,635 shares of the medical research company’s stock worth $511,000 after buying an additional 173 shares during the period. Simon Quick Advisors LLC lifted its holdings in shares of Amgen by 22.1% in the 2nd quarter. Simon Quick Advisors LLC now owns 2,882 shares of the medical research company’s stock worth $901,000 after buying an additional 521 shares during the period. Finally, Foundations Investment Advisors LLC grew its position in shares of Amgen by 16.7% during the 2nd quarter. Foundations Investment Advisors LLC now owns 14,940 shares of the medical research company’s stock worth $4,668,000 after buying an additional 2,134 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Stock Performance

NASDAQ:AMGN traded up $1.76 during mid-day trading on Friday, hitting $261.04. The company’s stock had a trading volume of 240,638 shares, compared to its average volume of 1,237,882. The business’s fifty day moving average is $285.75 and its two-hundred day moving average is $310.70. The stock has a market cap of $140.32 billion, a price-to-earnings ratio of 33.42, a PEG ratio of 2.91 and a beta of 0.55. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85.

Amgen (NASDAQ:AMGN) last issued its earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. The firm had revenue of $8.50 billion for the quarter, compared to the consensus estimate of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The company’s revenue was up 23.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $4.96 earnings per share. Analysts anticipate that Amgen Inc. will post 19.53 EPS for the current fiscal year.

Amgen Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be given a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a yield of 3.65%. The ex-dividend date is Friday, February 14th. This is a positive change from Amgen’s previous quarterly dividend of $2.25. Amgen’s dividend payout ratio (DPR) is currently 121.90%.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on AMGN. Piper Sandler lowered their price objective on shares of Amgen from $344.00 to $310.00 and set an “overweight” rating for the company in a research note on Thursday. Leerink Partners dropped their price objective on shares of Amgen from $349.00 to $302.00 in a research note on Wednesday, November 27th. Citigroup reduced their price objective on shares of Amgen from $335.00 to $310.00 in a research note on Wednesday, November 27th. TD Cowen lifted their price target on Amgen from $381.00 to $383.00 and gave the company a “buy” rating in a report on Monday, October 21st. Finally, William Blair restated an “outperform” rating on shares of Amgen in a research note on Tuesday, November 12th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Amgen presently has an average rating of “Hold” and a consensus price target of $318.83.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.